Balanced Risk-Reward and Fading Upside Visibility Keep AbbVie at Market-Perform (Hold) with $225 Target

Courtney Breen, an analyst from Bernstein, maintained the Hold rating on AbbVie. The associated price target remains the same with $225.00.

Courtney Breen has given his Hold rating due to a combination of factors related to AbbVie’s recent performance and outlook. The latest quarter’s earnings beat was heavily dependent on Humira rather than the newer growth drivers, which raises questions about the quality and sustainability of the upside. Skyrizi’s outperformance versus expectations has narrowed and Rinvoq missed consensus for the first time in several years, suggesting that the period of consistent, sizable beats from AbbVie’s key immunology assets may be fading. In addition, while management delivered highly detailed 2026 guidance that is modestly above consensus, they chose not to reaffirm or extend targets beyond that horizon, leaving investors uncertain about longer‑term growth momentum and upside catalysts.

At the same time, Breen notes that management’s current stance on M&A is more oriented toward building the longer‑term pipeline than creating meaningful earnings accretion and new stock catalysts in the near and medium term. With updated modeling that slightly trims 2026 revenue and EPS estimates, the risk‑reward profile looks more balanced than compelling, especially with competitive pressures building in immunology and IBD. The stock already reflects much of the anticipated growth from Skyrizi, Rinvoq, and CGRP assets, and without clear visibility into post‑2026 upside, there is limited justification for a more bullish stance. Taken together, these factors support a Market‑Perform (Hold) rating and a maintained price target of $225, rather than an upgrade to a more positive recommendation.

According to TipRanks, Breen is a 4-star analyst with an average return of 18.9% and an 84.62% success rate. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Merck & Company.

In another report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $226.00 price target.